Učitavanje...
Preclinical Evaluation of Recombinant T-cell Receptor Ligand RTL1000 as a Therapeutic Agent in Ischemic Stroke
Recombinant T-cell Receptor Ligand 1000 (RTL1000), a partial human major histocompatibility complex (MHC) molecule coupled to a human myelin peptide, reduces infarct size after experimental stroke in HLA-DRB1*1502 transgenic (DR2-Tg) mice. In this study, we characterized the therapeutic time window...
Spremljeno u:
| Izdano u: | Transl Stroke Res |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2014
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4298461/ https://ncbi.nlm.nih.gov/pubmed/25270354 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12975-014-0373-7 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|